Nadejda Valtcheva
Overview
Explore the profile of Nadejda Valtcheva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
728
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagner U, Wong C, Camenisch U, Zimmermann K, Rechsteiner M, Valtcheva N, et al.
J Mol Diagn
. 2022 Jun;
24(8):935-954.
PMID: 35718092
Next-generation sequencing has greatly advanced the molecular diagnostics of malignant hematological diseases and provides useful information for clinical decision making. Studies have shown that certain mutations are associated with prognosis...
2.
Valtcheva N, Nguyen-Strauli B, Wagner U, Freiberger S, Varga Z, Britschgi C, et al.
Exp Mol Pathol
. 2021 Oct;
123:104705.
PMID: 34637782
PARP inhibitors are used for treatment of tumors lacking function of the double-strand DNA break repair proteins BRCA1 or BRCA2 and are already approved for several cancer types. Thus, it...
3.
Wyvekens N, Valtcheva N, Mischo A, Helmchen B, Hermanns T, Choschzick M, et al.
Genes Chromosomes Cancer
. 2020 Jun;
59(11):611-619.
PMID: 32537760
The hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC) is defined by germline mutations in the fumarate hydratase (FH) gene and associated with leiomyomas and aggressive renal cell carcinomas with...
4.
Leao R, Lee D, Figueiredo A, Hermanns T, Wild P, Komosa M, et al.
Int J Cancer
. 2018 Oct;
144(7):1676-1684.
PMID: 30350309
In urothelial bladder cancer (UBC), risk stratification remains an important unmet need. Limitless self-renewal, governed by TERT expression and telomerase activation, is crucial for cancer progression. Thus, telomerase activation through...
5.
Velizheva N, Rechsteiner M, Valtcheva N, Freiberger S, Wong C, Vrugt B, et al.
Pathol Res Pract
. 2018 Mar;
214(4):572-578.
PMID: 29580750
Oncogenic rearrangements leading to targetable gene fusions are well-established cancer driver events in lung adenocarcinoma. Accurate and reliable detection of these gene fusions is crucial to select the appropriate targeted...
6.
Valtcheva N, Lang F, Noske A, Samartzis E, Schmidt A, Bellini E, et al.
BMC Cancer
. 2017 Jan;
17(1):66.
PMID: 28103826
Background: Endometrioid adenocarcinoma of the uterus and ovarian endometrioid carcinoma share many morphological and molecular features. Differentiation between simultaneous primary carcinomas and ovarian metastases of an endometrial cancer may be...
7.
Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, et al.
Oncotarget
. 2016 Sep;
8(9):14794-14805.
PMID: 27582547
One TCGA subgroup of endometrial cancer (EC) is characterised by extensive genomic DNA copy number alterations. CCNE1 located at 19q12 is frequently amplified in EC and a target for anti-cancer...
8.
Church D, Stelloo E, Nout R, Valtcheva N, Depreeuw J, Ter Haar N, et al.
J Natl Cancer Inst
. 2014 Dec;
107(1):402.
PMID: 25505230
Background: Current risk stratification in endometrial cancer (EC) results in frequent over- and underuse of adjuvant therapy, and may be improved by novel biomarkers. We examined whether POLE proofreading mutations,...
9.
Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong C, Noske A, et al.
J Pathol
. 2014 Jun;
234(2):239-52.
PMID: 24930886
Endometrial cancer is the most frequently occurring malignancy of the female genital tract in Western countries. Although in many cases surgically curable, about 30% of the tumours represent an aggressive...
10.
Valtcheva N, Primorac A, Jurisic G, Hollmen M, Detmar M
J Biol Chem
. 2013 Nov;
288(50):35736-48.
PMID: 24178298
The important role of the lymphatic vascular system in pathological conditions such as inflammation and cancer has been increasingly recognized, but its potential as a pharmacological target is poorly exploited....